(A) Immunofluorescence of γH2AX and Lamin A/C and quantification of γH2AX and nuclear abnormalities in LAKI 4F TTFs subjected to cyclic expression of OSKM for the indicated days. Scale bar, 10 μm. *p < 0.05, **p < 0.005, ***p < 0.0005, and ****p < 0.0001 according to one-way ANOVA with Bonferroni correction compared to control.
(B) Immunofluorescence and quantification of H3K9me3 in LAKI 4F TTFs subjected to cyclic expression of OSKM for the indicated days. Scale bar, 10 μm. ***p < 0.0005 and ****p < 0.0001 according to one-way ANOVA with Bonferroni correction.
(C) Immunofluorescence and quantification of H3K9me3 in LAKI 4F TTFs subjected to short-term expression of OSKM for 12 hr and 24 hr. Scale bar, 10 μm. **p < 0.005 and ****p < 0.0001 according to one-way ANOVA with Bonferroni correction.
(D) Immunofluorescence of γH2AX and Lamin A/C, and quantification of γH2AX and nuclear abnormalities in LAKI 4F TTFs subjected to short-term expression of OSKM for 12 hr and 24 hr. Scale bar, 10 μm.
(E) Immunofluorescence and quantification of H3K9me3 in LAKI 4F TTFs subjected to short-term expression of OSKM in the presence of the H3K9 methyl-transferase inhibitor chaetocin. Scale bar, 10 μm. **p < 0.01 and ****p < 0.0001 according to one-way ANOVA with Bonferroni correction.
(F) Immunofluorescence and quantification of γH2AX foci in LAKI 4F TTFs subjected to short-term expression of OSKM in the presence of the H3K9 methyl-transferase inhibitor chaetocin. Scale bar, 10 μm. ****p < 0.0001 according to one-way ANOVA with Bonferroni correction.
Data are presented as mean ± SEM.